Genelux (NASDAQ:GNLX) Raised to “Sell” at Wall Street Zen

Genelux (NASDAQ:GNLX) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Sunday.

GNLX has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research note on Friday, July 17th. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a research report on Tuesday, August 18th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Stock Performance

Genelux stock opened at $2.72 on Friday. Genelux has a twelve month low of $2.29 and a twelve month high of $8.53. The stock has a 50 day moving average of $2.86 and a two-hundred day moving average of $2.77. The stock has a market capitalization of $123.07 million, a price-to-earnings ratio of -3.16 and a beta of 0.60.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Equities analysts predict that Genelux will post -0.81 earnings per share for the current year.

Insider Buying and Selling

In other Genelux news, Director John Thomas sold 10,000 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $2.98, for a total transaction of $29,800.00. Following the sale, the director directly owned 472,784 shares in the company, valued at approximately $1,408,896.32. The trade was a 2.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director John W. Smither sold 12,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the sale, the director directly owned 91,403 shares in the company, valued at $265,982.73. This trade represents a 11.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 25,868 shares of company stock valued at $76,120. Insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Genelux

Several institutional investors and hedge funds have recently made changes to their positions in GNLX. Creative Planning increased its holdings in Genelux by 4.7% during the 3rd quarter. Creative Planning now owns 46,108 shares of the company’s stock valued at $194,000 after acquiring an additional 2,084 shares in the last quarter. Raymond James Financial Inc. lifted its holdings in shares of Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after purchasing an additional 5,333 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after purchasing an additional 5,596 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Genelux during the 4th quarter worth approximately $48,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Genelux during the 2nd quarter worth approximately $35,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.